8-KOther EventsExhibits & Filings

BOSTON SCIENTIFIC CORP 8-K Report, Corporate Update (Jun 11, 2019)

Filed June 11, 2019For Securities:BSX

Summary

Boston Scientific Corporation (BSX) announced the successful completion of its acquisition of Vertiflex, Inc. on June 11, 2019. This strategic move, previously announced in May 2019, signifies Boston Scientific's expansion into the interventional pain management market, specifically targeting patients suffering from lumbar spinal stenosis (LSS). Vertiflex's key product, the Superion® Indirect Decompression System, offers a minimally invasive solution to alleviate pain and improve physical function for this patient population. The acquisition is expected to enhance Boston Scientific's product portfolio in the pain management segment, a growing area within the medical device industry. Investors should view this as a positive step towards diversifying revenue streams and capitalizing on unmet needs in the treatment of LSS, a condition affecting a significant number of individuals.

Key Highlights

  • 1Boston Scientific Corporation (BSX) has completed the acquisition of Vertiflex, Inc. as of June 11, 2019.
  • 2The acquisition was initially announced on May 9, 2019.
  • 3Vertiflex is known for its Superion® Indirect Decompression System.
  • 4The Superion® system is a minimally-invasive device for treating lumbar spinal stenosis (LSS).
  • 5This acquisition expands BSX's presence in the interventional pain management market.
  • 6The closing of the acquisition followed the satisfaction of customary closing conditions.
  • 7A press release regarding the acquisition closing is included as an exhibit.

Frequently Asked Questions

The acquisition of Vertiflex strengthens Boston Scientific's position in the interventional pain management sector, particularly in addressing lumbar spinal stenosis (LSS). It adds a minimally invasive device, the Superion® system, to their product portfolio, potentially driving revenue growth and catering to a significant patient need.

Vertiflex is a privately-held company that developed and commercialized the Superion® Indirect Decompression System. This system is designed for minimally invasive treatment of lumbar spinal stenosis (LSS) to reduce pain and improve physical function.

The definitive agreement to acquire Vertiflex was initially announced by Boston Scientific on May 9, 2019.

This particular 8-K filing does not disclose specific financial terms or the purchase price of the Vertiflex acquisition. Such details may have been provided in the press release (Exhibit 99.1) or may be subject to future SEC filings.